v

PGT-A

Right Embryo
Unique innovation to improve the odds of pregnancy and IVF success

pgt-a-

pgt-a-icon

PGT-A

Right Embryo
Unique innovation to improve the odds of pregnancy and IVF success

The only test using artificial intelligence (AI) based on clinical outcome data, eliminating subjectivity, and improving accuracy.

Using two independent analyses (CNV & SNP) to check for abnormalities, providing greater confidence in robust and accurate results.

icon

>13% increase in ongoing pregnancy and live birth rates vs standard PGT-A¹

Emerging Evidence

Patients’ chances of having a baby improved
with the PGTaiSM 2.0 Platform!

A single-center study shows the innovative
PGTai 2.0 platform helped patients fulfill
their ultimate dream of having a baby by
increasing ongoing pregnancy
and live birth rates.

Watch our PGT-Complete Webinar

Key Product Information

NYU-graph-data

Introducing PGT-A with PTA

We are implementing Primary Template-directed Amplification (PTA), a novel approach to DNA amplification for embryo biopsy samples.

This innovation represents the first major advancement to DNA amplification since 2009 and marks a milestone in improving the quality of DNA amplification in embryo samples.

This change is being implemented because CooperSurgical Genomics, hopes to provide the most advanced technology available to you and your patients which means from time-to-time upgrades to our technology require that we permanently discontinue outdated processes.

If you have any queries or would like any further information please click here to contact your Territory Account Manager or Clinical Support Specialist.

There are no required changes to your clinical processes.

No, there is no added cost to PGT-A testing.

No, at this time we do not anticipate any changes to our key performance metrics.

No, there will not be any changes to the report format or delivery.

No, only samples received after February 19th 2024, will be processed by PTA

There will be a grace period of 90 days (up to May 20th 2024) to submit buccal swabs and documentation related to any PGT-A cases that were analyzed between the dates of Dec 1st 2021 and Feb 19th 2024. During this period our laboratory staff will be happy to conduct retrospective PGT- Complete.

YES! Once we have transitioned to the new processes any cases received after Feb 19th 2024 will have the option of conducting PGT-Complete retrospectively. Remember, PGT-A cases submitted between Dec 1st 2021 and Feb 19th 2024 will NO longer be eligible for retrospective PGT-Complete after May 20th 2024.

We transitioned amplification for PGT-M cases to PTA starting in Feb of 2023. Only older cases, or those otherwise amplified by a different technology are impacted.

We are providing a 6-month period (until Aug 20th 2024) for our partners to finalize analysis of any embryos held in storage at our CooperGenomics® locations.

Laboratory Process Improvement Timeline

Don’t forget to mark your calendar with these important dates
Excluding New York State samples and samples sent to our UK-based laboratory

PTA Timeline

NIPGT_A Research

NIPGT-A Research Update

Our dedication to investigation and innovation expands to non-invasive methodologies.

Mosaic

Our overview of the paper:

1,000 Mosaic Embryo Transfers Viotti et al, 2021

Watch Our Webinars

  • The Past, Present and Future of PGT-M

  • Mosaicism: The Power Of Knowing

  • PGT-Complete: A new standard of care to reduce anxiety and increase transfer opportunity

  • Using your genetic testing clinic report to support and streamline your KPI data

Clinic Testimonials

At CARE Fertility, we have been impressed with the transition from standard to PGTai; the staff education and clarity of reporting. In addition, we are reassured by the increased precision of this test and believe it brings benefits for our patients.

Alison Campbell
Director of Embryology, CARE Fertility Group, London, UK

The switch to PGTai has more than halved the turnaround time on our results, with the lab now averaging 3 days from sample receipt to providing us with the final report. That’s been an enormous benefit, those extra few days waiting for results make a huge difference to our patients! We’ve seen a drop in the number of ‘no call’ results since the changeover to below 2%. Most importantly the level of service from the staff we deal with in the UK laboratory has been outstanding, always friendly, helpful and on top of anything we need.

Kelli Sorby
Scientific Director, Number1 Fertility, Melbourne, Australia

PGT-A-icon

Download our PGT-A via:
PGTai Technology Platform
White Paper

PGT-A-icon

Download our PGT-A via:
PGTai Technology Platform
White Paper

Download our PGT-A via:
PGTai 2.0 Technology Platform
White Paper

Download our PGT-A via:
PGTai 2.0 Technology Platform
White Paper

EndometrialEnvironmentWhitetick width=

Download our PGT-A via:
PGT-Complete 
White Paper

EndometrialEnvironmentWhitetick width=

Download our PGT-A via:
PGT-Complete 
White Paper

Documents

1. Buldo-Licciardi J, Large M, McCulloh D, McCaffrey C, Grifo J. Second generation artificial intelligence technology for preimplantation genetic testing (PRT) improves pregnancy outcomes in single thawed euploid embryo transfer cycles (STEET). Presented at American Society for Reproductive Medicine on October 19, 2020.
Available at: https://asrm.confex.com/asrm/2020/meetingapp.cgi/Paper/8645. Accessed November 2, 2021. 2. CooperGenomics, internal data on file.